Study on Relieving Hyperuricemia and Gout Function by Limosilactobacillus reuteri HCS02-001

doi:10.19586/j.2095-2341.2024.0018

Current Biotechnology ›› 2024, Vol. 14 ›› Issue (3): 473-479.DOI: 10.19586/j.2095-2341.2024.0018

• Articles • Previous Articles Next Articles

Study on Relieving Hyperuricemia and Gout Function by Limosilactobacillus reuteri HCS02-001

Ping YU¹^,²(), Di ZHAO¹^,², Xuejiao CHEN¹^,², Jia SONG¹^,², Haitao WANG¹^,², Xiangbo MIN¹^,²

^1.Jiangxi Renren Health Microecological Technology Co. ，Ltd. ，Jiangxi Zhangshu 331200，China
^2.Renren Microbial Technology Research （Shenyang） Co. ，Ltd. ，Shenyang 110170，China

Received:2024-02-04 Accepted:2024-04-10 Online:2024-05-25 Published:2024-06-18

罗伊氏粘液乳杆菌HCS02-001缓解高尿酸血症及痛风功能的研究

余萍¹^,²(), 赵迪¹^,², 陈雪娇¹^,², 宋佳¹^,², 汪海涛¹^,², 闵祥博¹^,²

^1.江西仁仁健康微生态科技有限公司，江西樟树 331200
^2.仁仁微生物科技研究（沈阳）有限公司，沈阳 110170

作者简介:余萍E-mail: yuping18809871495@163.com
基金资助:
北京伍连德公益基金会科技创新项目(WU20220018)

Abstract

Abstract:

To explore the function of Limosilactobacillus reuteri HCS02-001 in relieving hyperuricemia and gout， it was inoculated in the culture medium containing inosine and guanosine for a certain period of time， and the content changes of inosine and guanosine in the reaction solution were determined to confirm its ability to decompose purine nucleosides in vitro. Then 63 patients with hyperuricemia were randomly divided into control group and intervention group. Both groups were treated with alkalized urine on the basis of basic treatment， and the intervention group was treated with Limosilactobacillus reuteri freeze-dried powder for 30 days. The results of functional test in vitro showed that after 1 hour of culture with Limosilactobacillus reuteri HCS02-001， the degradation rate of inosine and guanosine were 62.07% and 73.53%， respectively. After 2 hours of culture， the degradation rate of inosine and guanosine were 61.29% and 67.65%， respectively. The population experiment showed that Limosilactobacillus reuteri HCS02-001 could significantly increased the total clinical effective rate， reduced the content of serum uric acid， inflammatory factor serum C-reactive protein （CRP）， total cholesterol （TC）， triglycerides （TG）， and low-density lipoprotein cholesterol （LDL-C）， increased high-density lipoprotein cholesterol （HDL-C） levels. At the same time， it is safe to improve the phenomenon of joint bone erosion in patients. In conclusion， Limosilactobacillus reuteri HCS02-001 can effectively relieve hyperuricemia and gout without side effects.

Key words: gout, hyperuricemia, Limosilactobacillus reuteri, clincial effects, safety

摘要：

为探究罗伊氏粘液乳杆菌HCS02-001缓解高尿酸血症及痛风的功能，将罗伊氏粘液乳杆菌HCS02-001接种于含有肌苷、鸟苷培养液并培养一定时间后，通过测定反应液中肌苷与鸟苷含量变化来确认其体外嘌呤核苷的分解能力。将63例高尿酸血症患者随机分为对照组和干预组，2组均在基础治疗上给予碱化尿液处理，干预组额外给予罗伊氏粘液乳杆菌HCS02-001冻干粉，疗程为30 d。体外功能试验结果发现，添加罗伊氏粘液乳杆菌HCS02-001培养1 h后，肌苷与鸟苷的降解率分别为62.07%、73.53%；培养2 h后，二者的降解率分别为61.29%和67.65%。人群实验结果发现，罗伊氏粘液乳杆菌HCS02-001可显著提高患者临床总有效率，降低血清尿酸、炎症因子血清C反应蛋白（C-reactive protein，CRP）及总胆固醇（total cholesterol，TC）、甘油三酯（triglycerides，TG）和低密度脂蛋白胆固醇（low-density lipoprotein cholesterol，LDL-C）的含量，提高高密度脂蛋白胆固醇（high-density lipoprotein cholesterol，HDL-C）含量，同时改善患者关节骨侵蚀现象，且具有安全性。结果表明，罗伊氏粘液乳杆菌HCS02-001可有效缓解高尿酸血症及痛风，且无不良反应。

关键词: 痛风, 高尿酸血症, 罗伊氏粘液乳杆菌, 临床疗效, 安全性

CLC Number:

Q939.9

Ping YU, Di ZHAO, Xuejiao CHEN, Jia SONG, Haitao WANG, Xiangbo MIN. Study on Relieving Hyperuricemia and Gout Function by Limosilactobacillus reuteri HCS02-001[J]. Current Biotechnology, 2024, 14(3): 473-479.

余萍, 赵迪, 陈雪娇, 宋佳, 汪海涛, 闵祥博. 罗伊氏粘液乳杆菌HCS02-001缓解高尿酸血症及痛风功能的研究[J]. 生物技术进展, 2024, 14(3): 473-479.

Figures/Tables 9

References 19

1	KUO Y W, HHSIEH S, CHEN J F, et al.. Lactobacillus reuteri TSR332 and Lactobacillus fermentum TSF331 stabilize serum uric acid levels and prevent hyperuricemia in rats[J/OL]. PeerJ, 2021, 9: e11209[2024-04-15]. .
2	LEE Y, WERLINGER P, WSUH J, et al.. Potential probiotic Lacticaseibacillus paracasei MJM60396 prevents hyperuricemia in a multiple way by absorbing purine, suppressing xanthine oxidase and regulating urate excretion in mice[J/OL]. Microorganisms, 2022, 10(5): 851[2024-04-15]. .
3	ZENG L, DENG Y, HE Q, et al.. Safety and efficacy of probiotic supplementation in 8 types of inflammatory arthritis: a systematic review and meta-analysis of 34 randomized controlled trials[J/OL]. Front. Immunol., 2022, 13: 961325[2024-04-15]. .
4	WANG Z, SONG L, LI X, et al.. Lactiplantibacillus pentosus P2020 protects the hyperuricemia and renal inflammation in mice[J/OL]. Front. Nutr., 2023, 10: 1094483[2024-04-15]. .
5	HSIEH F C, LAN C C, HUANG T Y, et al.. Heat-killed and live Lactobacillus reuteri GMNL-263 exhibit similar effects on improving metabolic functions in high-fat diet-induced obese rats[J]. Food Funct., 2016, 7(5): 2374-2388.
6	HSIEH M C, TSAI W H, JHENG Y P, et al.. The beneficial effects of Lactobacillus reuteri ADR-1 or ADR-3 consumption on type 2 diabetes mellitus: a randomized, double-blinded, placebo-controlled trial[J/OL]. Sci. Rep., 2018, 8(1): 16791[2024-04-15]. .
7	余萍,闵祥博,汪海涛,等.罗伊氏粘液乳杆菌HC S02-001降尿酸应用及产品: CN116585362A[P].2023-08-15.
8	周启蒙,赵晓悦,孔德文,等.桑色素对高尿酸血症模型小鼠肝肾功能及血糖和血脂水平的影响及其机制[J].中国药理学与毒理学杂志,2021,35(8):595-601.
	ZHOU Q M, ZHAO X Y, KONG D W, et al.. Effect and mechanism of morin on liver and kidney function, blood glucose and lipids in hyperuricemia model mice[J]. Chin. J. Pharmacol. Toxicol., 2021, 35(8): 595-601.
9	XIAO Y, ZHANG C, ZENG X, et al.. Microecological treatment of hyperuricemia using Lactobacillus from pickles[J/OL]. BMC Microbiol., 2020, 20(1): 195[2024-04-15]. .
10	ZHAO H, LU Z, LU Y. The potential of probiotics in the amelioration of hyperuricemia[J]. Food Funct., 2022, 13(5): 2394-2414.
11	RODRÍGUEZ J M, GARRANZO M, SEGURA J, et al.. A randomized pilot trial assessing the reduction of gout episodes in hyperuricemic patients by oral administration of Ligilactobacillus salivarius CECT 30632, a strain with the ability to degrade purines[J/OL]. Front. Microbiol., 2023, 14: 1111652[2024-04-15]. .
12	YAMANAKA H, TANIGUCHI A, TSUBOI H, et al.. Hypouricaemic effects of yoghurt containing Lactobacillus gasseri PA-3 in patients with hyperuricaemia and/or gout: a randomised, double-blind, placebo-controlled study[J]. Mod. Rheumatol., 2019, 29(1): 146-150.
13	ZHAO S, FENG P, HU X, et al.. Probiotic Limosilactobacillus fermentum GR-3 ameliorates human hyperuricemia via degrading and promoting excretion of uric acid[J/OL]. iScience, 2022, 25(10): 105198[2024-04-15]. .
14	黄金时,肖永深,梁逸仙.祛瘀清热汤治疗痛风的疗效及对血清C反应蛋白白细胞介素6及肿瘤坏死因子α水平的影响[J].实用医技杂志,2021,28(10):1174-1177.
	HUANG J S, XIAO Y S, LIANG Y X. Curative effect of Quyu Qingre Decoction in treating gout and its influence on serum C-reaction protein interleukin-6 and tumor necrosis factor-α levels[J]. J. Pract. Med. Tech., 2021, 28(10): 1174-1177.
15	吴冕.高尿酸血症动物模型构建及相关并发症研究[D].上海:上海交通大学,2019.
16	孙萌潞.高尿酸血症的影响因素及血尿酸与血清学指标间的关联性研究[D].锦州:锦州医科大学,2021.
17	WANG H, MEI L, DENG Y, et al.. Lactobacillus brevis DM9218 ameliorates fructose-induced hyperuricemia through inosine degradation and manipulation of intestinal dysbiosis[J]. Nutrition, 2019, 62: 63-73.
18	WU Y, YE Z, FENG P, et al.. Limosilactobacillus fermentum JL-3 isolated from "Jiangshui" ameliorates hyperuricemia by degrading uric acid[J]. Gut Microbes, 2021, 13(1): 1-18.
19	CAO J, BU Y, HAO H, et al.. Effect and potential mechanism of Lactobacillus plantarum Q7 on Hyperuricemia in vitro and in vivo [J/OL]. Front. Nutr., 2022, 9: 954545[2024-04-15]. .

类别	组别	培养1 h后浓度/(g·L^-1)	降解率/%	培养2 h后浓度/(g·L^-1)	降解率/%
肌苷	空白对照组	0.29		0.31
肌苷	HCS02-001组	0.11	62.07	0.12	61.29
鸟苷	空白对照组	0.34		0.34
鸟苷	HCS02-001组	0.09	73.53	0.11	67.65

类别	组别	培养1 h后浓度/(g·L^-1)	降解率/%	培养2 h后浓度/(g·L^-1)	降解率/%
肌苷	空白对照组	0.29		0.31
肌苷	HCS02-001组	0.11	62.07	0.12	61.29
鸟苷	空白对照组	0.34		0.34
鸟苷	HCS02-001组	0.09	73.53	0.11	67.65

分组	显效/例	有效/例	无效/例	总有效率/%
对照组	2	8	9	52.6
干预组	6	27	8	80.5*

分组	显效/例	有效/例	无效/例	总有效率/%
对照组	2	8	9	52.6
干预组	6	27	8	80.5*

分组	时间点	血尿酸/(μmol·L^-1)
对照组（n=19）	治疗前	453.74±20.20
对照组（n=19）	治疗后	411.53±68.95*
干预组（n=41）	治疗前	452(440.5, 473.05)
干预组（n=41）	治疗后	369.27±68.93**#

Study on Relieving Hyperuricemia and Gout Function by Limosilactobacillus reuteri HCS02-001

罗伊氏粘液乳杆菌HCS02-001缓解高尿酸血症及痛风功能的研究

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 9

References 19

Related Articles 15

Recommended Articles

Metrics

Comments

分组	时间点	血清CRP水平/(mg·L^-1)
对照组（n=19）	治疗前	3.87±1.78
对照组（n=19）	治疗后	3.56±1.40
干预组（n=41）	治疗前	3.73±1.78
干预组（n=41）	治疗后	2.67±1.59**

分组	时间点	骨侵蚀评分
对照组（n=4）	治疗前	3.50±1.29
对照组（n=4）	治疗后	3.25±1.40
干预组（n=9）	治疗前	3.89±1.27
干预组（n=9）	治疗后	3.00±1.12

分组	时间点	TC/(mmol·L^-1)	TG/(mmol·L^-1)	HDL-C/(mmol·L^-1)	LDL-C/(mmol·L^-1)
对照组（n=19）	治疗前	5.38±1.59	2.13±0.88	1.36±0.38	3.56±1.07
对照组（n=19）	治疗后	5.26±1.41	1.84±0.70	1.37±0.32	3.18±1.14*
干预组（n=41）	治疗前	5.38±1.53	1.83(1.46, 2.31)	1.28(1.12, 1.52)	3.28±1.25
干预组（n=41）	治疗后	4.90±1.41**	1.48(1.10, 2.09)**	1.33(1.13, 1.69)*	2.82±1.15**

分组	时间点	白细胞/(×10⁹个·L^-1)	红细胞/(×10⁹个·L^-1)	血红蛋白/(g·L^-1)	血小板/(×10⁹个·L^-1)
对照组（n=19）	治疗前	6.58±1.28	4.56(4.25, 5.23)	143.16±11.69	231.16±45.67
对照组（n=19）	治疗后	6.28±1.15	4.73(4.28, 5.31)	144.63±16.19	212.63±62.23
干预组（n=41）	治疗前	6.42(5.72, 7.19)	4.73±0.103	140.63±2.84	231.88±46.12
干预组（n=41）	治疗后	6.32(5.65, 6.07)	4.75±0.096	138.85±2.81	235.46±48.33

分组	时间点	丙转氨酶/(U·L^-1)	谷草转氨酶/(U·L^-1)	白蛋白/(g·L^-1)
对照组（n=19）	治疗前	18.4(12.8, 27.1)	20(17.0, 25.2)	39.89±4.94
对照组（n=19）	治疗后	19.5(14.6, 24.1)	17(15.8, 25.0)	40.48±5.26
干预组（n=41）	治疗前	22(17.5, 29.0)	20.1(16.85, 28.5.0)	42.06(37.48, 44.60)
干预组（n=41）	治疗后	20(15.95, 25.16)	20.3(17.90, 25.98)	42.00(36.83, 44.34)

分组	时间点	血肌酐/(μmol·L^-1)	尿素氮/(mmol·L^-1)
对照组（n=19）	治疗前	90.74±28.49	6.38（5.4, 8.6）
对照组（n=19）	治疗后	94.67±30.22	6.90（5.1, 7.8）
干预组（n=41）	治疗前	88.18±24.45	6.70(4.66, 7.65)
干预组（n=41）	治疗后	88.90±24.51	5.69(4.41, 7.83)

[1]	Lingyan LI, Bing XIAO, Xudong ZHANG, Hua ZHANG, Ziyan CHEN, Haoqian WANG, Xiujie ZHANG, Hong CHEN, Jingang LIANG. Establishment and Standardization of Real-time PCR Method for Qualitative Detection of Genetically Modified Maize MON87411 [J]. Current Biotechnology, 2024, 14(2): 257-262.
[2]	Jia SONG, Xuelong LI, Xinmei LIN, Ping YU, Sicheng YANG, Yongzhen PENG, Yanping JIAO, Xuejiao CHEN. Study on Optimization of Culture Method and Improvement of Sleep Function of Limosilactobacillus reuteri HCS02-001 [J]. Current Biotechnology, 2024, 14(1): 133-140.
[3]	Yonghong ZHANG, Yanyi LI, Weiting ZHANG. Progress on Integration Site Analysis Technology [J]. Current Biotechnology, 2024, 14(1): 66-71.
[4]	Yingrui GAO, Fuzhong KANG, Tiejian MENG, Kefei LIU, Tiaotiao WANG, Jinyan CHEN, Tong SUN. Safety Evaluation of Clostridium butyricum Based on Whole Genome Sequencing [J]. Current Biotechnology, 2023, 13(5): 755-759.
[5]	Enze CHENG-CHEN, Minghong JIA, Yueying LI. Research Progress of Nucleic Acid Reference Materials of Food-borne Pathogenic Bacteria [J]. Current Biotechnology, 2023, 13(2): 195-200.
[6]	Doudou LEI, Runran MA, Jiabo WANG, Weijun KONG. Research Progress on New Biological Detection Technology for Pesticide Residues in Foods [J]. Current Biotechnology, 2023, 13(1): 1-10.
[7]	Jiaxin QIN, Baozhen YAO. Effects of Pregnancy Dexamethasone Exposure on Hippocampal Neuron Proliferation and Synaptic Plasticity of Rat Offspring [J]. Current Biotechnology, 2022, 12(6): 946-952.
[8]	Tingting LIU, Tao TONG, Kunlun HUANG. Research Progress and Safety Evaluation of Transgenic Corn [J]. Current Biotechnology, 2022, 12(4): 523-531.
[9]	Feng ZHANG, Xiaoyun HE, Kunlun HUANG, Qihuai WANG. Food Safety Evaluation of Transgenic Herbicide Tolerant Soybean [J]. Current Biotechnology, 2021, 11(4): 489-495.
[10]	JIAO Yue^1, ZHU Pengyu², LIANG Jingang¹, FU Wei^2. International Genetically Modified Food Safety Evaluation Policy and its Enlightenment [J]. Curr. Biotech., 2021, 11(2): 121-127.
[11]	XI Yuanyuan^§, XU Hongyan^§, LIU Xia, YIN Huiqing, LIU Xiaopan, WANG Qinglu, WANG Qinglu^*. Alleviating Effect of Tieguanyin Tea Aqueous Extract on Hyperuricemia in Mice [J]. Curr. Biotech., 2020, 10(3): 256-264.
[12]	HUANG Chunmeng1,2, ZHU Pengyu1, WANG Zhi1, WANG Chenguang1, DU Zhixin3, WEI Shuang4, ZHANG Yongjiang1, FU Wei1*. Regulatory Status and Challenges of RNAi-based Transgenic Plants in Breeding [J]. Curr. Biotech., 2020, 10(1): 10-14.
[13]	WU Chunlei1, WU Zhilin2, WU Jie2, JIANG Han2, ZANG Huawei2, TAN Genjia2, YUAN Linxi3, LI Miao2*. Progress on Application of Selenium in Plant Protection and Agricultural Products Quality and Safety [J]. Curr. Biotech., 2017, 7(5): 462-466.
[14]	DU Jian-zhong1, HAO Yao-shan1, WANG Yi-xue1, ZHANG Huan-huan1, SUN Yi1*, SHI Hong-wei2. Development, Challenges and Countermeasures for Industrialization of Genetically Modified Staple Crops in China [J]. Curr. Biotech., 2016, 6(3): 159-168.
[15]	LIU Xiao-zhi, ZHAO Wei, CHANG Liang, GAO Jian*. The Safe Use of a Chemiluminescence Detection Reagent Luminol [J]. Curr. Biotech., 2014, 4(3): 182-185.